MATTHEW CILIMBERG: Open Payments
NPI 1538676952 · EXTON, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$409 in 17 payments from 9 companies in 2025. Trend: 2023 $450 · 2024 $125 · 2025 $409
Food & beverage: $409
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 8 | $177 |
| AstraZeneca Pharmaceuticals LP | 2 | $65 |
| Regeneron Healthcare Solutions, Inc. | 1 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Novartis Pharmaceuticals Corporation | 1 | $26 |
| On Target Laboratories, Inc | 1 | $21 |
| Genentech USA, Inc. | 1 | $18 |
| Coherus Oncology, Inc. | 1 | $18 |
| JAZZ PHARMACEUTICALS INC. | 1 | $14 |
Products named: VENCLEXTA, LIBTAYO, EPKINLY, TAGRISSO, ALUNBRIG, SCEMBLIX, Cytalux, Tecentriq.
Industry payments across PA — which companies pay providers there.
